View More View Less
  • 1 Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China
  • 2 Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
Restricted access

Summary

Dauricine has a variety of pharmacological properties including anti-inflammatory, anti-arrhythmic, and antihypertensive effects as well as reversing multidrug resistance (MDR) of cancer cells. While its therapeutic application is increasing, its bioavailability of different administration routes has not been studied. In the present study, we developed and validated a liquid chromatography/electrospray ionization mass spectrometry method (LC-MS/MS). Using this method, we quantified dauricine in rat plasma after administration via intravenous (i.v.) injection, per oral (p.o.), and intraperitoneal injection (i.p.). Our results indicated that this method detected plasma dauricine with a good linearity in the range of 1.95–1000.00 ng/mL (r = 0.9997). The extraction method showed an average intra- and inter-day recovery of 98.21–104.35% and 98.0–103.58%, respectively. Dauricine showed a fast absorption and widespread distribution after administration in all three tested routes. After intravenous administration (2.5, 5.0, 10.0 mg/kg), the pharmacokinetics of dauricine exhibited a first-order kinetics. In addition, dauricine showed a slow elimination with a long half-life (t1/2z) and double peaks phenomenon following p.o. and i.p. administration. Furthermore, using area under the plasma concentration-time curve (AUC), we calculated absolute bioavailability, which was over twofold higher when administered via i.p. than via p.o. administration. The newly obtained information from our study will provide important reference for dauricine dose and administration route in designing dauricine therapy for applicable diseases.

  • [1]. M.C. Li D.Y. Huang 2008 Chin. Pharm. J. 43 18751877.

  • [2]. Z.K. Huang 2004 Modern Journal of Integrated Traditional Chinese and Western Medicine 13 718719.

  • [3]. Q.Y. Li J.Y. Wang J.J. Cheng 2010 Progress in Veterinary Medicine 31 115117.

  • [4]. Pharmacopoeia Commission of People's Republic of China. Pharmacopoeia of People's Republic of China, 1st edn. Chemical Industry Press, Beijing, 2005.

    • Search Google Scholar
    • Export Citation
  • [5]. Y. Zhang C. Sun Q.C. Guan 2009 Modern Pharmacy and Clinic 24 367368.

  • [6]. M. Li B.E. Shan 2005 International Journal of Traditional Chinese Medicine 27 267271.

  • [7]. X.Q. Zhu T.G. Han 2007 Journal of Chengde Medical College 24 418420.

  • [8]. X.D. Huang D. Han X.Y. Cui 2007 Medical Journal of Chinese People's Health 19 575576.

  • [9]. J.Q. Qian 2002 Acta Pharmacol Sin 23 10861092.

  • [10]. H. Tian Q.C. Pan 1996 Cancer 15 410414.

  • [11]. J.H. Li F.Q. Qin P.M. Yang 2002 Journal of Dalian Medical University 24 9496.

  • [12]. L. He G.Q. Liu 2002 Acta Pharmacol Sin 23 591596.

  • [13]. F.M. Han Z.H. Peng W. Song 2007 Journal of Chromatography B 854 17.

  • [14]. X.Y. Liu Q. Liu D.M. Wang 2010 Journal of Chromatography B 878 11991203.

  • [15]. S.J. Chen B. Zhang Y.M. Yang Z.S. Dai 2000 Chinese Journal Of Clinical Pharmacology and Therapeutics 5 213217.

  • [16]. S.J. Chen Y.M. Yang 2001 Chinese Pharmacological Bulletin 17 225229.

  • [17]. R. Sun C. Wang 2009 Chinese Journal of Pharmacovigilance 6 546549.

  • [18]. V.J. Wacher L. Salphati L.Z. Benet 2001 Advanced Drug Delivery Reviews 46 89102.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2020 0 2 0
Jun 2020 0 1 2
Jul 2020 0 1 0
Aug 2020 2 0 0
Sep 2020 1 0 0
Oct 2020 0 0 0
Nov 2020 0 0 0